Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
about
Self-assembling protein nanoparticles in the design of vaccinesSystems biology from virus to humansTackling a novel lethal virus: a focus on H7N9 vaccine development.Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy AdultsZoonotic infections with avian influenza A viruses and vaccine preparedness: a game of "mix and match"Influenza virus neuraminidase (NA): a target for antivirals and vaccines.One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge.Divergent H7 immunogens offer protection from H7N9 virus challenge.Preliminary success in the characterization and management of a sudden breakout of a novel H7N9 influenza A virus.Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design.Identifying areas with a high risk of human infection with the avian influenza A (H7N9) virus in East AsiaResponse of mice and ferrets to a monovalent influenza A (H7N9) split vaccine.Mammalian models for the study of H7 virus pathogenesis and transmission.Considerations for the rapid deployment of vaccines against H7N9 influenza.Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs.Emerging influenza viruses and the prospect of a universal influenza virus vaccine.Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.Critical assessment of influenza VLP production in Sf9 and HEK293 expression systems.Progress in developing virus-like particle influenza vaccines.Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1.Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity.Multi-antigen avian influenza a (H7N9) virus-like particles: particulate characterizations and immunogenicity evaluation in murine and avian models.Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferretsA single dose of whole inactivated H7N9 influenza vaccine confers protection from severe disease but not infection in ferrets.Evaluation of MDCK cell-derived influenza H7N9 vaccine candidates in ferretsNewcastle Disease Virus-Vectored H7 and H5 Live Vaccines Protect Chickens from Challenge with H7N9 or H5N1 Avian Influenza Viruses.Effect of AcHERV-GmCSF as an Influenza Virus Vaccine AdjuvantGeneration and Characterization of Live Attenuated Influenza A(H7N9) Candidate Vaccine Virus Based on Russian Donor of Attenuation.Emergence of H7N9 Influenza A Virus Resistant to Neuraminidase Inhibitors in Nonhuman Primates.Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of ProtectionRecombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virusCharacterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.Suboptimal Humoral Immune Response against Influenza A(H7N9) Virus Is Related to Its Internal Genes.Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.Genotyping and detection of common avian and human origin-influenza viruses using a portable chemiluminescence imaging microarray.Self-assembled HCV core virus-like particles targeted and inhibited tumor cell migration and invasion.Cross-protective efficacy of dendritic cells targeting conserved influenza virus antigen expressed by Lactobacillus plantarum.Update on baculovirus as an expression and/or delivery vehicle for vaccine antigens.Enveloped virus-like particles as vaccines against pathogenic arboviruses.The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors.
P2860
Q26767097-FBDBA157-C240-4924-82FE-5CF78A7105DFQ26798272-FE7625C1-2F5C-4410-8EA9-D1D214A99B5AQ30148631-C3508DB2-4799-48C4-AD40-598F8E9B3E92Q30151798-E6EB7764-1039-47BE-8827-FF50DA3C21A3Q30209434-DEA0AEFE-C355-4E5C-BB4A-845785D77A6DQ30249879-DAF202B0-DF89-4E4D-8F73-4466EA16F72EQ30355863-3DA2229D-7482-4264-850B-C7AB8C9492E2Q30358196-CAB85B0D-E82B-4410-A169-36FCDED72471Q30358886-1B255F30-529D-4414-94E1-97A1AF90C720Q30358954-99DA93C1-7CE1-4871-B73B-71A39FE9C3EAQ30360330-42E4C20D-D2A5-4808-97B8-051E8AE6123BQ30363689-EC5186E0-75E0-4A0D-974A-087ED553C80EQ30364385-84EAC6A6-B473-4740-81F6-2DB8C7C08FEAQ30364635-212CC985-F673-44AD-8CDC-20803B019699Q30372141-F5261D0C-D19D-4989-ADCD-C8DA9C94712CQ30372274-A25056DF-7985-4D7E-A7B0-B7D46393B94FQ30372696-08E9FBAF-20F5-412D-930A-679C9FA96C01Q30374733-45770C7B-791D-4F7E-AA94-3E9226AFB21AQ30386640-E4DA1B10-F308-4877-9756-B395EECE109EQ30387699-350C4274-10B6-4584-9568-E3CDF8AABBB8Q30392895-8468F394-0BE6-4FC7-A0C7-1286C187D388Q30397144-48146578-E327-4FA8-9335-67492661D831Q33743763-3CC7E2B6-3D25-4A16-B809-11DA546E522AQ33931916-C36ABB17-F2C1-4CA7-A01E-63399079CCA2Q35208516-9C5337DA-5FC0-4D47-B97A-6AC07F687CA5Q35618503-DF0A6590-80E1-47B2-B1E7-4226AF888244Q35668481-C90800AC-9C99-4F30-8483-082C7713E330Q35787563-76633000-87EE-434F-896E-AD828321AB44Q35860081-FCF75539-8383-4D88-BE50-BB4381874572Q35990859-2668DED3-AD2A-4F54-9043-1BA636996BE2Q36037316-1B71397E-0A6B-42C4-BCE9-41748FD5742DQ36076240-A52D0473-2067-48E6-BF9A-03DDA6477981Q36316782-36A7E267-A417-4DB7-98E5-C1B2EBEED049Q36408162-7FF728E9-BC86-484F-95EE-1853489D1762Q37366083-C85689F3-0F24-48C9-9644-C00B4849EF52Q37376522-FF644077-71AA-43B4-B6A8-EA80C6DF7AECQ37525971-8E9764F7-77FF-4B43-9EA8-5474CFD3A984Q38243160-064CEB69-CC98-434F-8F60-486D0C5FBADBQ38359973-A0F38F97-46EC-4692-9109-A01CE4DB06CEQ38388047-DB5BF28B-BD89-4E24-B59A-B57B6958A06F
P2860
Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Development of influenza H7N9 ...... ce challenged with H7N9 virus.
@ast
Development of influenza H7N9 ...... ce challenged with H7N9 virus.
@en
type
label
Development of influenza H7N9 ...... ce challenged with H7N9 virus.
@ast
Development of influenza H7N9 ...... ce challenged with H7N9 virus.
@en
prefLabel
Development of influenza H7N9 ...... ce challenged with H7N9 virus.
@ast
Development of influenza H7N9 ...... ce challenged with H7N9 virus.
@en
P2093
P1433
P1476
Development of influenza H7N9 ...... ce challenged with H7N9 virus.
@en
P2093
David C Flyer
Denise Courbron
Eloi Kpamegan
Gale E Smith
Gregory M Glenn
Louis F Fries
Ramadevi Raghunandan
Yingyun Wu
Ziping Wei
P304
P356
10.1016/J.VACCINE.2013.07.043
P407
P577
2013-07-26T00:00:00Z